Advaxis (ADXS) 10-Q 13 Mar 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Jan. 31, 2015	Mar. 09, 2015
Document And Entity Information
Entity Registrant Name	Advaxis, Inc.
Entity Central Index Key	1100397
Document Type	10-Q
Document Period End Date	31-Jan-15
Amendment Flag	FALSE
Current Fiscal Year End Date	-21
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		27,208,826
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2015

Balance_Sheets

Balance Sheets (USD $)	Jan. 31, 2015	Oct. 31, 2014
Current Assets:
Cash	$30,577,964	$17,606,860
Prepaid Expenses	51,037	182,978
Income Tax Receivable		1,731,317
Other Current Assets	8,182	8,182
Deferred Expenses - current	882,467	964,724
Total Current Assets	31,519,650	20,494,061
Property and Equipment (net of accumulated depreciation)	70,467	77,369
Intangible Assets (net of accumulated amortization)	2,920,929	2,767,945
Other Assets	38,438	38,438
TOTAL ASSETS	34,549,484	23,377,813
Current Liabilities:
Accounts Payable	1,524,694	1,411,058
Accrued Expenses	1,257,260	1,241,796
Short-Term Convertible Notes and Fair Value of Embedded Derivative	62,882	62,882
Total Current Liabilities	2,844,836	2,715,736
Common Stock Warrant Liability	304,331	32,091
Total Liabilities	3,149,167	2,747,827
Commitments and Contingencies
Shareholders' Equity:
Preferred Stock, $0.001 par value; 5,000,000 shares authorized; Series B Preferred Stock; issued and outstanding 0 at January 31, 2015 and October 31, 2014. Liquidation preference of $0 at January 31, 2015 and October 31, 2014.
Common Stock - $0.001 par value; authorized 45,000,000 shares, issued and outstanding 24,021,955 at January 31, 2015 and 19,630,139 at October 31, 2014.	24,021	19,630
Additional Paid-In Capital	125,401,303	107,601,493
Accumulated Deficit	-94,025,007	-86,991,137
Total Shareholders' Equity	31,400,317	20,629,986
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$34,549,484	$23,377,813

Balance_Sheets_Parenthetical

Balance Sheets (Parenthetical) (USD $)	Jan. 31, 2015	Oct. 31, 2014
Statement of Financial Position [Abstract]
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Preferred stock, liquidation preference value	$0	$0
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	45,000,000	45,000,000
Common stock, shares issued	24,021,955	19,630,139
Common stock, shares outstanding	24,021,955	19,630,139

Statements_of_Operations_Unaud

Statements of Operations (Unaudited) (USD $)	3 Months Ended
	Jan. 31, 2015	Jan. 31, 2014
Income Statement [Abstract]
Revenue
Operating Expenses
Research and Development Expenses	3,579,936	1,559,867
General and Administrative Expenses	3,196,099	4,397,836
Total Operating Expenses	6,776,035	5,957,703
Loss from Operations	-6,776,035	-5,957,703
Other Income (Expense):
Interest Expense		-2,015
Gain on Note retirement		6,243
Net changes in fair value of derivative liabilities	-264,071	131,948
Other Income	6,236	8,572
Loss before benefit for income taxes	-7,033,870	-5,812,955
Income Tax Benefit		625,563
Net Loss	($7,033,870)	($5,187,392)
Net Loss per share, basic and diluted	($0.33)	($0.37)
Weighted Average Number of Shares Outstanding, Basic and Diluted	21,551,169	13,842,144

Statements_of_Cash_Flows_Unaud

Statements of Cash Flows (Unaudited) (USD $)	3 Months Ended
	Jan. 31, 2015	Jan. 31, 2014
OPERATING ACTIVITIES
Net Loss	($7,033,870)	($5,187,392)
Adjustments to reconcile Net Loss to net cash used in operating activities:
Non-cash charges to consultants and employees for options and stock	2,030,170	1,602,423
Non-cash interest expense		51
Loss (Gain) on change in value of warrants and embedded derivative	264,071	-131,948
Warrant expense	8,169	1,482
Settlement expense		34,125
Employee Stock Purchase Plan	1,700	5,371
Depreciation expense	6,902	6,903
Amortization expense of intangibles	48,303	41,934
(Gain) on note retirement		-6,243
Change in operating assets and liabilities:
Prepaid expenses	131,941	17,116
Income tax receivable	1,731,317
Other current assets		-75,000
Deferred expenses	82,257	105,018
Accounts payable and accrued expenses	129,100	-1,371,578
Interest payable		1,964
Net cash used in operating activities	-2,599,940	-4,955,774
INVESTING ACTIVITIES
Purchase of property and equipment		-24,595
Cost of intangible assets	-201,287	-12,427
Net cash used in Investing Activities	-201,287	-37,022
FINANCING ACTIVITIES
Net proceeds of issuance of Common Stock	15,772,331	400,000
Net cash provided by Financing Activities	15,772,331	400,000
Net increase (decrease) in cash	12,971,104	-4,592,796
Cash at beginning of period	17,606,860	20,552,062
Cash at end of period	30,577,964	15,959,266
Supplemental Schedule of Non-cash Investing and Financing Activities
Accounts Payable from consultants settled with Common Stock		$3,000

Organization

Organization	3 Months Ended
	Jan. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization	1. ORGANIZATION
	Advaxis, Inc. (“Advaxis” or the “Company”) is a clinical stage biotechnology company focused on the discovery, development and commercialization of proprietary Lm-LLO cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (“Lm” or “Listeria”), bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-LLO strains are believed to be a significant advancement in immunotherapy as they integrate multiple functions into a single immunotherapy as they access and direct antigen presenting cells to stimulate anti-tumor T-cell immunity, stimulate and activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable the T-cells to eliminate tumors.
	ADXS-HPV is Advaxis’s lead Lm-LLO immunotherapy product candidate for the treatment of human papilloma virus (“HPV”) associated cancers. The Company completed a randomized Phase 2 study in 110 patients with recurrent cervical cancer that demonstrated a manageable safety profile, improved survival and objective tumor responses. In addition, the Gynecologic Oncology Group (“GOG”), now part of NRG Oncology, is conducting a Phase 2 open-label clinical study of ADXS-HPV in patients with persistent or recurrent cervical cancer with documented disease progression. The study, known as GOG 0265, has successfully completed its first stage and has met the predetermined safety and efficacy criteria required to proceed into the second stage of patient recruitment which is now enrolling. The Company plans to advance this immunotherapy into a registrational clinical trial for the treatment of women with high-risk locally advanced cervical cancer.
	ADXS-HPV has received United States Food and Drug Administration (“FDA”) orphan drug designation for three HPV-associated cancers: cervical, head and neck, and anal cancer, and is being evaluated in three ongoing investigator-initiated clinical trials as follows: locally advanced cervical cancer (cooperative group sponsor), head and neck cancer, and anal cancer. In addition to the investigator-initiated clinical trials, Company-sponsored trials executed under an Investigational New Drug (“IND”) include the following: i) a Phase 1/2 clinical trial alone and in combination with MedImmune’s investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in patients with previously treated metastatic HPV-associated cervical cancer and HPV-associated head and neck cancer; ii) a Phase 2 multi-center, open-label study alone and in combination with Incyte’s investigational oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, epacadostat (INCB24360) in patients with Stage I-IIa HPV-associated cervical cancer; iii) a Phase 1/2 study evaluating higher doses and repeat cycles of ADXS-HPV in patients with recurrent cervical cancer; and, iv) a Phase 2 study in collaboration with and funded by Global BioPharma Inc. (“GBP”), under a development and commercialization license agreement applicable to Asia, of ADXS-HPV in HPV-associated non-small cell lung cancer.
	ADXS-PSA is the Company’s Lm-LLO immunotherapy product candidate designed to target the Prostate Specific Antigen (“PSA”) associated with prostate cancer. The FDA has cleared the Company’s IND application to commence a Phase 1/2 clinical trial alone and in combination with KEYTRUDA® (pembrolizumab), Merck’s humanized monoclonal antibody against PD-1, in patients with previously treated metastatic castration-resistant prostate cancer.
	ADXS-HER2 is the Company’s Lm-LLO immunotherapy product candidate designed for the treatment of Human Epidermal Growth Factor Receptor 2 (“HER2”) expressing cancers, including human and canine osteosarcoma, breast, gastric and other cancers. The FDA has cleared the Company’s IND application and plans to initiate a Phase 1b clinical trial in patients with metastatic HER2 expressing solid tumors. The Company received orphan drug designation for ADXS-HER2 in osteosarcoma. Clinical research with ADXS-HER2 in canine osteosarcoma is being developed by the Company’s pet therapeutic partner, Aratana Therapeutics Inc. (“Aratana”), who holds exclusive rights to develop and commercialize ADXS-HER2 and three other Lm-LLO immunotherapies for pet health applications. Aratana has announced that a product license application for use of ADXS-HER2 in the treatment of canine osteosarcoma has been filed with the United States Department of Agriculture (“USDA”). Aratana received communication from the USDA in March 2015 that the efficacy data previously submitted for product license for AT-014 (ADXS-HER2), the cancer vaccine for canine osteosarcoma, licensed from the Company was accepted to provide a reasonable expectation of efficacy to support conditional licensure. While Aratana needs to complete additional steps, including in the areas of manufacturing and safety, Aratana anticipates that AT-014 could receive conditional licensure from the USDA in 2016.
	Since inception in 2002, the Company has focused its development efforts on understanding its platform technology and establishing a drug development pipeline that incorporates this technology into therapeutic cancer immunotherapies, currently those targeting HPV-associated cancer (cervical cancer, head and neck cancer and anal cancer), prostate cancer, and HER2 expressing cancers. Although no immunotherapies have been commercialized to date, research and development and investment continues to be placed behind the advancement of this technology. Pipeline development and the further exploration of the technology for advancement entails risk and expense. The Company anticipates that its ongoing operational costs will increase significantly as it continues conducting and expanding its clinical development program. Further, over twenty distinct additional constructs leveraging certain antigens highly expressed in multiple tumor types, developed directly by the Company and through strategic collaborations with recognized centers of excellence, are in various stages of development. Impending priority research advances include, but are not limited to, constructs targeting pan tumor antigens and tumor stromal targets.
	Liquidity and Financial Condition
	The Company’s products are being developed and have not generated significant revenues. As a result, the Company has suffered recurring losses. These losses are expected to continue for an extended period of time. On December 19, 2014, the Company priced a registered direct offering of 3,940,801 shares of its Common Stock (“Common Stock”). The transaction closed on December 22, 2014, and the Company received net proceeds of approximately $15.8 million from the offering. In addition, on February 18, 2015, the Company priced an additional registered direct offering of 3,068,095 shares of its Common Stock. The transaction closed on February 19, 2015, and the Company received net proceeds of approximately $22.3 million from the offering. The shares in each offering were sold under a Registration Statement (No. 333-194009) on Form S-3, filed by the Company with the SEC. The Company believes its current cash position is sufficient to fund its business plan approximately until first calendar quarter 2017. We have based this estimate on assumptions that may prove to be wrong, and we could use available capital resources sooner than currently expected. Because of the numerous risks and uncertainties associated with the development and commercialization of its product candidates, we are unable to estimate the amount of increased capital outlays and operating expenses associated with completing the development of our current product candidates.
	The Company recognizes it may need to raise additional capital over and above the amount raised during December 2014 and February 2015 in order to continue to execute its business plan. Subsequent to January 31, 2015, the Company intends to continue to raise additional funds through sales of equity securities. There is no assurance that additional financing will be available when needed or that management will be able to obtain financing on terms acceptable to the Company or whether the Company will become profitable and generate positive operating cash flow. If the Company is unable to raise sufficient additional funds, it will have to scale back its business plan.

Summary_of_Significant_Account

Summary of Significant Accounting Policies and Basis of Presentation	3 Months Ended
	Jan. 31, 2015
Accounting Policies [Abstract]
Summary of Significant Accounting Policies and Basis of Presentation	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION
	Basis of Presentation - Unaudited Interim Financial Information
	The accompanying unaudited interim condensed financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information, and in accordance with the rules and regulations of the United States Securities and Exchange Commission (the “SEC”) with respect to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect all adjustments (consisting of normal recurring accruals) which are, in the opinion of management, necessary to represent a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. These unaudited interim financial statements should be read in conjunction with the financial statements of the Company for the year ended October 31, 2014 and notes thereto contained in the Company’s annual report on Form 10-K for the year ended October 31, 2014, as filed with the SEC on January 6, 2015.
	Revenue Recognition
	The Company is expected to derive the majority of its revenue from patent licensing in the near term. In general, these revenue arrangements provide for the payment of contractually determined fees in consideration for the grant of certain intellectual property rights for patented technologies owned or controlled by the Company. The intellectual property rights granted may be perpetual in nature, or upon the final milestones being met, or can be granted for a defined, relatively short period of time, with the licensee possessing the right to renew the agreement at the end of each contractual term for an additional minimum upfront payment. The Company recognizes licensing fees when there is persuasive evidence of a licensing arrangement, fees are fixed or determinable, delivery has occurred and collectability is reasonably assured.
	An allowance for doubtful accounts is established based on the Company’s best estimate of the amount of probable credit losses in the Company’s existing license fee receivables, using historical experience. The Company reviews its allowance for doubtful accounts periodically. Past due accounts are reviewed individually for collectability.
	Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. To date, this is yet to occur.
	If product development is successful, the Company will recognize revenue from royalties based on licensees’ sales of its products or products using its technologies. Royalties are recognized as earned in accordance with the contract terms when royalties from licensees can be reasonably estimated and collectability is reasonably assured. If royalties cannot be reasonably estimated or collectability of a royalty amount is not reasonably assured, royalties are recognized as revenue when the cash is received.
	The Company recognizes revenue from milestone payments received under collaboration agreements when earned, provided that the milestone event is substantive, its achievability was not reasonably assured at the inception of the agreement, the Company has no further performance obligations relating to the event and collection is reasonably assured. If these criteria are not met, the Company recognizes milestone payments ratably over the remaining period of the Company’s performance obligations under the collaboration agreement. All such recognized revenues are included in collaborative licensing and development revenue in the Company’s consolidated statements of operations.
	Estimates
	The preparation of financial statements in accordance with GAAP involves the use of estimates and assumptions that affect the recorded amounts of assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results may differ substantially from these estimates. Significant estimates include the fair value and recoverability of the carrying value of intangible assets (patents and licenses), the fair value of options, the fair value of embedded conversion features, warrants and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, based on historical experience and on various other assumptions that it believes to be reasonable under the circumstances. Actual results may differ from estimates.
	Concentration of Credit Risk
	The Company maintains its cash in bank deposit accounts (checking) that at times exceed federally insured limits. Approximately $30.3 million is subject to credit risk at January 31, 2015. However, these cash balances are maintained at creditworthy financial institutions. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk.
	Fair Value of Financial Instruments
	The carrying amounts of financial instruments, including cash, accounts payable and accrued expenses approximated fair value as of the balance sheet date presented, because of the relatively short maturity dates on these instruments. The carrying amounts of the financing arrangements issued approximate fair value as of the balance sheet date presented, because interest rates on these instruments approximate market interest rates after consideration of stated interest rates, anti-dilution protection and associated warrants.
	Net Loss per Share
	Basic net income or loss per common share is computed by dividing net income or loss available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share give effect to dilutive options, warrants, convertible debt and other potential Common Stock outstanding during the period. In the case of a net loss the impact of the potential Common Stock resulting from warrants, outstanding stock options and convertible debt are not included in the computation of diluted loss per share, as the effect would be anti-dilutive. In the case of net income the impact of the potential Common Stock resulting from these instruments that have intrinsic value are included in the diluted earnings per share. The table sets forth the number of potential shares of Common Stock that have been excluded from diluted net loss per share.
		As of January 31,
		2015		2014
	Warrants		4,082,248		4,360,441
	Stock Options		477,968		467,923
	Convertible Debt (using the if-converted method)		3,354		3,354
	Total		4,563,570		4,831,718
	Stock Based Compensation
	The Company has an equity plan which allows for the granting of stock options to its employees, directors and consultants for a fixed number of shares with an exercise price equal to the fair value of the shares at date of grant. The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally measured based on contractual terms. The fair value amount is then recognized over the requisite service period, usually the vesting period, in both research and development expenses and general and administrative expenses on the statement of operations depending on the nature of the services provided by the employees or consultants.
	The process of estimating the fair value of stock-based compensation awards and recognizing stock-based compensation cost over their requisite service period involves significant assumptions and judgments. The Company estimates the fair value of stock option awards on the date of grant using the Black Scholes Model (“BSM”) for the remaining awards, which requires that the Company makes certain assumptions regarding: (i) the expected volatility in the market price of its Common Stock; (ii) dividend yield; (iii) risk-free interest rates; and (iv) the period of time employees are expected to hold the award prior to exercise (referred to as the expected holding period). As a result, if the Company revises its assumptions and estimates, stock-based compensation expense could change materially for future grants.
	The Company accounts for stock-based compensation using fair value recognition and records stock-based compensation as a charge to earnings net of the estimated impact of forfeited awards. As such, the Company recognizes stock-based compensation cost only for those stock-based awards that are estimated to ultimately vest over their requisite service period, based on the vesting provisions of the individual grants.
	Recent Accounting Pronouncements
	In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers. Amendments in this ASU create Topic 606, Revenue from Contracts with Customers, and supersede the revenue recognition requirements in Topic 605, Revenue Recognition, including most industry-specific revenue recognition guidance throughout the Industry Topics of the Codification. In addition, the amendments supersede the cost guidance in Subtopic 605-35, Revenue Recognition—Construction-Type and Production-Type Contracts, and create new Subtopic 340-40, Other Assets and Deferred Costs—Contracts with Customers. In summary, the core principle of Topic 606 is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This ASU is the final version of Proposed ASU 2011-230—Revenue Recognition (Topic 605) and Proposed ASU 2011–250—Revenue Recognition (Topic 605): Codification Amendments, both of which have been deleted. The amendments in this ASU are effective for the Company for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. The Company is currently evaluating the effects of ASU 2014-09 on the consolidated financial statements.
	In January 2015, the FASB issued ASU 2015-01, Income Statement —Extraordinary and Unusual Items. The objective of this Update is to simplify the income statement presentation requirements in Subtopic 225-20 by eliminating the concept of extraordinary items. Extraordinary items are events and transactions that are distinguished by their unusual nature and by the infrequency of their occurrence. Eliminating the extraordinary classification simplifies income statement presentation by altogether removing the concept of extraordinary items from consideration. This Accounting Standards Update is the final version of Proposed Accounting Standards Update 2014-220—Income Statement—Extraordinary Items (Subtopic 225-20), which has been deleted. The amendments in this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. This Update is not expected to have a material impact on the Company’s financial statements.
	Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on the accompanying condensed financial statements.

Property_and_Equipment

Property and Equipment	3 Months Ended
	Jan. 31, 2015
Property, Plant and Equipment [Abstract]
Property and Equipment	3. PROPERTY AND EQUIPMENT
	Property and equipment consists of the following:
		January 31, 2015			October 31, 2014
			(Unaudited)
	Laboratory Equipment	$	333,727		$	333,727
	Accumulated Depreciation		(263,260	)		(256,358	)
	Net Property and Equipment	$	70,467		$	77,369
	Depreciation expense for the three months ended January 31, 2015 and 2014 was $6,902 and $6,903, respectively.

Intangible_Assets

Intangible Assets	3 Months Ended
	Jan. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	4. INTANGIBLE ASSETS
	Pursuant to our license agreement with the University of Pennsylvania, the Company is billed actual patent expenses as they are passed through from Penn and are billed directly from our patent attorney. The following is a summary of intangible assets as of the end of the following fiscal periods:
		January 31, 2015			October 31, 2014
			(Unaudited)
	License	$	651,992		$	651,992
	Patents		3,312,911			3,111,624
	Total intangibles		3,964,903			3,763,616
	Accumulated Amortization		(1,043,974	)		(995,671	)
	Intangible Assets	$	2,920,929		$	2,767,945
	The expirations of the existing patents range from 2015 to 2028 but the expirations can be extended based on market approval if granted and/or based on existing laws and regulations. Capitalized costs associated with patent applications that are abandoned without future value are charged to expense when the determination is made not to pursue the application. No patent applications with future value were abandoned or expired and charged to expense in the three months ended January 31, 2015 or 2014. Amortization expense for licensed technology and capitalized patent costs are included in general and administrative expenses and aggregated $48,303 and $41,934 for the three months ended January 31, 2015 and 2014, respectively.
	Estimated amortization expense for the next five years is as follows:
	Year ended October 31,
	2015 (Remaining)		148,500
	2016		198,000
	2017		198,000
	2018		198,000
	2019		198,000

Accrued_Expenses

Accrued Expenses	3 Months Ended
	Jan. 31, 2015
Payables and Accruals [Abstract]
Accrued Expenses	5. ACCRUED EXPENSES:
	The following table represents the major components of accrued expenses:
		January 31, 2015		October 31, 2014
		(Unaudited)
	Salaries and Other Compensation	$	583,895	$	890,069
	Vendors		420,002		121,200
	Professional Fees		205,401		208,000
	Withholding Taxes Payable		47,962		22,527
		$	1,257,260	$	1,241,796

ShortTerm_Convertible_Notes_Fa

Short-Term Convertible Notes & Fair Value of Embedded Derivative	3 Months Ended
	Jan. 31, 2015
Debt Disclosure [Abstract]
Short-Term Convertible Notes & Fair Value of Embedded Derivative	6. SHORT-TERM CONVERTIBLE NOTES & FAIR VALUE OF EMBEDDED DERIVATIVE
	As of January 31, 2015 and October 31, 2014, the Company had approximately $63,000 in principal outstanding on its junior subordinated convertible promissory notes that are currently overdue and are recorded as current liabilities on our balance sheet at January 31, 2015 and October 31, 2014.

Derivative_Instruments

Derivative Instruments	3 Months Ended
	Jan. 31, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments	7. DERIVATIVE INSTRUMENTS
	Warrants
	A summary of changes in warrants for the three months ended January 31, 2015 is as follows:
		Number of			Weighted-Average
		Warrants			Exercise Price
	Outstanding Warrants at October 31, 2014:		4,158,092		$	5.42
	Issued		2,361		$	7.2
	Exercised		-			-
	Expired		(78,205	)	$	9.79
	Outstanding Warrants at January 31, 2015		4,082,248		$	5.21
	At January 31, 2015, the Company had approximately 4.0 million of its total 4.1 million outstanding warrants classified as equity (equity warrants). At October 31, 2014, the Company had approximately 4.1 million of its total 4.2 million outstanding warrants classified as equity (equity warrants). At issuance, equity warrants are recorded at their relative fair values, using the Relative Fair Value Method, in the shareholders’ equity section of the balance sheet. The equity warrants can only be settled through the issuance of shares and are not subject to anti-dilution provisions.
	Warrant Liability/Embedded Derivative Liability
	Warrant Liability
	At January 31, 2015, the Company had 61,000 of its total 4.1 million outstanding warrants classified as liability warrants (liability warrants). As of October 31, 2014, the Company had approximately 123,000 of its total approximately 4.2 million total warrants classified as liabilities (liability warrants). All of these liability warrants at January 31, 2015 and October 31, 2014 were outstanding. The Company utilizes the BSM to calculate the fair value of these warrants at issuance and at each subsequent reporting date. For those warrants with exercise price reset features (anti-dilution provisions), the Company computes multiple valuations, each quarter, using an adjusted BSM, to account for the various possibilities that could occur due to changes in the inputs to the BSM as a result of contractually-obligated changes (for example, changes in strike price to account for down-round provisions). The Company effectively weights each calculation based on the likelihood of occurrence to determine the value of the warrants at the reporting date. At January 31, 2015, approximately 32,000 of the 61,000 liability warrants are subject to weighted-average anti-dilution provisions. At October 31, 2014, approximately 60,000 of the 123,000 liability warrants are subject to weighted-average anti-dilution provisions. A certain number of liability warrants contain a cash settlement provision in the event of a fundamental transaction (as defined in the Common Stock purchase warrant). Any changes in the fair value of the warrant liability (i.e. - the total fair value of all outstanding liability warrants at the balance sheet date) between reporting periods will be reported on the statement of operations.
	At January 31, 2015 and October 31, 2014, the fair value of the warrant liability was approximately $304,000 and $32,000, respectively. For the three months ended January 31, 2015 and January 31, 2014, the Company reported a loss of approximately $264,000 and a gain of approximately $132,000, respectively, due to changes in the fair value of the warrant liability. In fair valuing the warrant liability, at January 31, 2015 and October 31, 2014, the Company used the following inputs in its BSM:
			1/31/15			10/31/14
	Exercise Price:	$	5.63-18.75		$	2.76-21.25
	Stock Price	$	9.85		$	3.18
	Expected term:		31-914 days			4-1006 days
	Volatility %		97.11%-184.64	%		55.41%-129.38	%
	Risk Free Rate:		.01%-.77	%		.01%-1.62	%
	Expiration of Warrants
	During the three months ended January 31, 2015, the Company had 30,400 warrants with anti-dilution provisions, and 47,805 warrants, with no such anti-dilution provisions, expire unexercised.
	Warrants with anti-dilution provisions
	Some of the Company’s warrants (approximately 30,000) contain anti-dilution provisions originally set at $25.00 with a term of five years. As of January 31, 2015, these warrants had an exercise price of approximately $7.20. As of October 31, 2014, these warrants had an exercise price of approximately $7.71. If the Company issues any Common Stock, except for exempt issuances as defined in the warrant agreement, for consideration less than the exercise price then the exercise price and the amount of warrant shares available would be adjusted to a new price and amount of shares per the “weighted average” formula included in the warrant agreement. For the three months ended January 31, 2015, this anti-dilution provision required the Company to issue approximately 2,400 additional warrant shares; and the exercise price to be lowered to $7.20. Any future financial offering or instrument issuance below the current exercise price of $7.20 will cause further anti-dilution and re-pricing provisions in approximately 30,000 of its total outstanding warrants.
	For those warrants with exercise price reset features (anti-dilution provisions), the Company computes multiple valuations, each quarter, using an adjusted BSM, to account for the various possibilities that could occur due to changes in the inputs to the BSM as a result of contractually-obligated changes (for example, changes in strike price to account for down-round provisions). The Company utilized different exercise prices of $7.20 and $6.00, weighting the possibility of warrants being exercised at $7.20 between 40% and 50% and warrants being exercised at $6.00 between 60% and 50%.
	As of January 31, 2015, there were outstanding warrants to purchase 4,082,248 shares of the Company’s Common Stock with exercise prices ranging from $2.76 to $21.25 per share.

Stock_Options

Stock Options	3 Months Ended
	Jan. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock Options	8. STOCK OPTIONS:
	A summary of changes in the stock option plan for three months ended January 31, 2015 is as follows:
		Number of			Weighted-Average
		Options			Exercise Price
	Outstanding at October 31, 2014:		467,968		$	15.51
	Granted		20,000		$	2.92
	Exercised		(4,229	)	$	4.08
	Expired		(5,771	)	$	4.08
	Outstanding at January 31, 2015		477,968		$	15.22
	Vested and Exercisable at January 31, 2015		446,035		$	15.69
	Total compensation cost related to our outstanding stock options, recognized in the statement of operations for the three months ended January 31, 2015, was $146,846 of which $45,229 was included in research and development expenses and $101,627 was included in general and administrative expenses. Total compensation cost related to our outstanding stock options, recognized in the statement of operations for the three months ended January 31, 2014, was $257,486 of which $90,380 was included in research and development expenses and $167,106 was included in general and administrative expenses.
	During the three months ended January 31, 2015, 20,000 options were issued for investor relations services with a grant date fair value of $57,600.
	There were no options granted during the three months ended January 31, 2014.
	As of January 31, 2015, there was approximately $125,000 of unrecognized compensation cost related to non-vested stock option awards, which is expected to be recognized over a remaining average vesting period of 0.50 years.
	The aggregate intrinsic value of these outstanding options, as of January 31, 2015, was approximately $282,000.

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
	Jan. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	9. COMMITMENTS AND CONTINGENCIES:
	Employment Agreements
	Management voluntarily purchases restricted stock directly from the Company at market price. The respective stock purchases occur on the last trading day of each month. This voluntary election is outlined in each of Daniel J. O’Connor, Chief Executive Officer and President, David J. Mauro, Executive Vice President, Chief Medical Officer, Gregory T. Mayes, Executive Vice President, Chief Operating Officer and Secretary, Robert G. Petit, Executive Vice President, Chief Scientific Officer, and Sara M. Bonstein, Senior Vice President, Chief Financial Officer (each an “Executive”), employment agreements. The table below reflects the purchases of each Executive:
		ANNUALIZED
		Annual Amount		For the Three Months Ended January 31, 2015
		to be Purchased		Gross Purchase				Net Purchase
	Executive	$		$		# of		$		# of
						shares				shares
	Daniel J. O’Connor	$	85,647	$	22,294		3,777	$	22,294		3,777
	David J. Mauro	$	15,918	$	4,256		726	$	3,290		580
	Gregory T. Mayes	$	20,951	$	5,453		924	$	4,425		773
	Robert G. Petit	$	25,145	$	6,610		1,123	$	4,856		882
	Sara M. Bonstein	$	17.651	$	4,617		783	$	3,632		630
	For the three months ended January 31, 2015, the Company recorded stock compensation expense of $46,153 on the statement of operations representing 7,832 shares of its Common Stock (7,053 shares on a net basis after employee payroll taxes).
	From 2013 to present, in addition to the purchases of Common Stock set forth in the above table, Mr. O’Connor has also purchased an additional 146,616 shares of Common Stock out of his personal funds at the then market price for an aggregate consideration of approximately $588,294. These purchases consisted of the conversion of amounts due to Mr. O’Connor under a promissory note given by Mr. O’Connor to the Company in 2012 of approximately $66,500 for 21,091 shares, 2013 base salary which he elected to receive in Common Stock of approximately $182,919 for 34,752 shares, 2013 and 2014 cash bonus voluntarily requested to receive in equity of approximately $206,125 for 57,990 shares, 2014 voluntary request to purchase stock directly from the Company at market price purchases of $68,750 for 15,950 shares, and purchases of the Company’s Common Stock in the October 2013 and March 2014 public offerings of 13,500 shares for $54,000 and 3,333 shares for $10,000.
	The Executive’s employment agreements entitle them to a performance-based year-end cash bonus. Mr. O’Connor, Dr. Mauro and Mr. Mayes voluntarily requested to be paid all of their bonus, required to be paid in cash, in the Company’s Common Stock instead of cash. Ms. Bonstein voluntarily requested to be paid 75% of her cash bonus in the Company’s Common Stock instead of cash. Dr. Petit received 100% of his bonus in cash. The total fair value of these equity purchases were $457,125, or 137,275 shares of the Company’s Common Stock (104,461 on a net basis after employee payroll taxes).
	Stock Awards
	During the three months ended January 31, 2015, 34,094 shares of Common Stock (27,566 shares on a net basis after employee taxes) were issued to executives and employees related to incentive retention awards, employment inducements and employee excellence awards. Accordingly, $133,699 was charged to stock compensation expense.
	Furthermore, non-executive employees were entitled to receive a performance-based year-end cash bonus. Several non-executive employees requested to be paid all or a portion of their cash bonus in the Company’s Common Stock instead of cash. The total fair value of these equity purchases were $28,164, or 8,458 shares of the Company’s Common Stock (8,442 on a net basis after employee payroll taxes).
	The Company recognizes the fair value of those vested shares in the statement of operations in the period earned.
	Director Compensation
	During the three months ended January 31, 2015, 191,939 shares of Common Stock (178,513 shares on a net basis after taxes) were issued to the Directors for compensation related to board and committee membership. Accordingly, $606,539 was charged to stock compensation expense.
	Legal Proceedings
	Iliad Research and Trading
	On March 24, 2014, Iliad Research and Trading, L.P. (“Iliad”) filed a complaint (the “Complaint”) against the Company in the Third Judicial District Court of Salt Lake County, Utah, purporting to assert claims for breach of express and implied contract. Specifically, Iliad alleged that the Company granted a participation right to Tonaquint, Inc. (“Tonaquint”) in a securities purchase agreement between Tonaquint and the Company, dated as of December 13, 2012 (the “Purchase Agreement”), pursuant to which Tonaquint was entitled to participate in any transaction that the Company structured in accordance with Section 3(a)(9) or Section 3(a)(10) of the Securities Act of 1933, as amended. Iliad further alleged that the settlement that the Company entered into with Ironridge Global IV, Ltd. (“Ironridge”), pursuant to which the Company issued certain shares of its Common Stock to Ironridge in reliance on the Section 3(a)(10) exemption, occurred without adequate notice for Tonaquint to exercise its participation right. In addition, Iliad alleged that it acquired all of Tonaquint’s rights under the Purchase Agreement in April 2013.
	On May 9, 2014, the Company filed papers in support of its motion to dismiss the Complaint in its entirety. On June 2, 2014, Iliad filed an amended complaint (the “Amended Complaint”), which purported to add claims against the Company under the federal and Utah securities laws and for common law fraud. On June 30, 2014, the Company removed the action to the United States District Court for the District of Utah. On August 1, 2014, after the Court issued its Order Granting Stipulated Motion for Leave to File Second Amended Complaint, Iliad filed a Second Amended Complaint (the “SAC”), which purported to add a sixth claim for conversion. On August 22, 2014, the Company filed papers in support of its motion to dismiss the SAC in its entirety. On November 24, 2014, the Court filed an order dismissing the conversion claim but denying the remainder of the motion to dismiss.
	Meanwhile, on September 22, 2014, Iliad filed papers in support of its motion for partial summary judgment of liability on the express contact claim. On December 5, 2014, Advaxis filed papers in opposition to the motion for partial summary judgment and in support of its separate motion under Rule 56(d) to deny partial summary judgment and for allowance of discovery. On December 8, 2014, Advaxis filed its answer to the SAC and a counterclaim (the “Counterclaim”), alleging that Iliad – by purporting to have surreptitiously preserved its claim for breach of Tonaquint’s alleged right to participate in the Ironridge transaction – had fraudulently induced Advaxis to enter into the parties’ post-assignment Exchange and Settlement Agreement and, in the alternative, had breached the covenant of good faith and fair dealing implied therein. On January 23, 2015, Iliad filed (i) reply papers in further support of its motion for partial summary judgment, (ii) papers in opposition to Advaxis’s motion under Rule 56(d) and (iii) its Reply to Counterclaim (rather than attempting to move to dismiss Advaxis’s Counterclaim). On March 11, 2015, the Court held argument on the partial motion for summary judgment and Rule 56(d) motion, and took both motions under advisement, but did not address the parties’ proposed Scheduling Order.
	Iliad seeks “damages in an amount to be determined at trial” (though the common law fraud damages alone are alleged to be “greater than $300,000”) plus interest, attorneys’ fees and costs. Iliad has also asked for punitive damages in connection with its claims under the Utah Securities Act (equal to three times its actual damages), and common law fraud. The Company intends to continue to defend itself vigorously.
	Numoda
	On June 19, 2009, the Company entered into a master agreement and on July 8, 2009, the Company entered into a Project Agreement with Numoda Corporation (“Numoda”), to oversee Phase 2 clinical activity with ADXS-HPV for the treatment of invasive cervical cancer and CIN.
	Numoda and the Company are in a dispute regarding the amounts outstanding under these agreements. Numoda had taken the position that it was owed approximately $540,000 while the Company believed that the amount due to Numoda should be substantially less than that amount. The Company intends to continue to defend itself vigorously.
	The Company is from time to time involved in legal proceedings in the ordinary course of its business. The Company does not believe that any of these claims and proceedings against us is likely to have, individually or in the aggregate, a material adverse effect on its financial condition or results of operations.
	Sale of Net Operating Losses (NOLs)
	The Company may be eligible, from time to time, to receive cash from the sale of its Net Operating Losses under the State of New Jersey NOL Transfer Program. In December 2014, the Company received a net cash amount of $1,731,317 from the sale of its state NOLs and research and development tax credits for the periods ended October 31, 2012 and 2013.
	Description of Property
	The Company’s corporate offices are currently located at 305 College Road East, Princeton, New Jersey 08540. On April 1, 2011, the Company entered into a sublease agreement for such office, which is an approximately 10,000 square foot leased facility in Princeton, NJ. The agreement has a termination date of November 29, 2015. The Company plans to continue to rent necessary offices and laboratories to support its business.

Sharesholders_Equity

Sharesholders' Equity	3 Months Ended
	Jan. 31, 2015
Equity [Abstract]
Sharesholders' Equity	10. SHAREHOLDERS’ EQUITY
	Registered Direct Offering
	On December 19, 2014, the Company priced a registered direct offering of 3,940,801 shares of its Common Stock at $4.25 per share. The transaction closed on December 22, 2014, and the Company received gross proceeds of approximately $16.7 million from the offering. After deducting offering expenses, the net proceeds from the offering were approximately $15.8 million.
	Shares Issued to consultants
	During the three months ended January 31, 2015, 90,000 shares of Common Stock valued at $698,100 were issued to consultants for investor relations services and 30,000 shares of Common Stock valued at $93,900 were issued to consultants for research and development services. The common stock share values were based on the grant date fair values.

Fair_Value

Fair Value	3 Months Ended
	Jan. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value	11. FAIR VALUE
	The authoritative guidance for fair value measurements defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or the most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Market participants are buyers and sellers in the principal market that are (i) independent, (ii) knowledgeable, (iii) able to transact, and (iv) willing to transact. The guidance describes a fair value hierarchy based on the levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:
	● Level 1 — Quoted prices in active markets for identical assets or liabilities
	● Level 2— Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or corroborated by observable market data or substantially the full term of the assets or liabilities
	● Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the value of the assets or liabilities
	The following table provides the liabilities carried at fair value measured on a recurring basis as of January 31, 2015 and October 31, 2014:
	January 31, 2015		Level 1		Level 2		Level 3		Total
	Common stock warrant liability, warrants exercisable at $2.76 - $21.25 from February 2015 through August 2017	$	-	$		$	304,331	$	304,331
	October 31, 2014		Level 1		Level 2		Level 3		Total
	Common stock warrant liability, warrants exercisable at $2.76 - $21.25 from November 2014 through August 2017	$	-	$		$	32,091	$	32,091
	Common stock warrant liability:
		January 31, 2015
		(Unaudited)
	Beginning balance: October 31, 2014	$	32,091
	Issuance of additional warrants due to anti-dilution provisions		8,169
	Change in fair value		264,071
	Balance at January 31, 2015	$	304,331

Subsequent_Events

Subsequent Events	3 Months Ended
	Jan. 31, 2015
Subsequent Events [Abstract]
Subsequent Events	12. SUBSEQUENT EVENTS
	Incyte Collaboration Agreement
	On February 10, 2015, the Company entered into a Clinical Study Collaboration Agreement (the “Incyte Agreement”) with Incyte Corporation (“Incyte”) for the development and analysis of a combination therapy for the treatment of cervical cancer (the “Study”). Under the terms of the Incyte Agreement, Incyte will contribute INCB024360, a selective Inhibitor of IDO1, and the Company will contribute ADXS-HPV to be dosed in combination during the course of the Study, with Incyte acting as the sponsor of the Study and taking the lead role in its conduct. Costs for the Study are to be split equally between the parties.
	Registered Direct Offering
	On February 18, 2015, the Company priced a registered direct offering of 3,068,095 shares of its Common Stock at $7.50 per share. The transaction closed on February 19, 2015, and the Company received gross proceeds of $23.0 million from the offering. After deducting offering expenses, the net proceeds from the offering were approximately $22.3 million.
	Recent Sales of Unregistered Securities
	On February 9, 2015, the Company issued 37,916 shares of Common Stock to an accredited investor as payment for consulting services rendered.
	On February 13, 2015, the Company issued 13,233 shares of Common Stock to a current Executive which represents the initial vesting period of an inducement grant pursuant to his Employment Agreement.
	On February 26, 2015, the Company issued 4,104 shares of Common Stock to accredited investors in consideration for converting notes payable totaling $33,333.
	On February 27, 2015, the Company issued 1,434 shares of Common Stock to management, pursuant to their Employment Agreements.
	On March 2, 2015, the Company issued 23,606 shares of Common Stock to accredited investors as payment for consulting services rendered.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies and Basis of Presentation (Policies)	3 Months Ended
	Jan. 31, 2015
Accounting Policies [Abstract]
Basis of Presentation - Unaudited Interim Financial Information	Basis of Presentation - Unaudited Interim Financial Information
	The accompanying unaudited interim condensed financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information, and in accordance with the rules and regulations of the United States Securities and Exchange Commission (the “SEC”) with respect to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect all adjustments (consisting of normal recurring accruals) which are, in the opinion of management, necessary to represent a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. These unaudited interim financial statements should be read in conjunction with the financial statements of the Company for the year ended October 31, 2014 and notes thereto contained in the Company’s annual report on Form 10-K for the year ended October 31, 2014, as filed with the SEC on January 6, 2015.
Revenue Recognition	Revenue Recognition
	The Company is expected to derive the majority of its revenue from patent licensing in the near term. In general, these revenue arrangements provide for the payment of contractually determined fees in consideration for the grant of certain intellectual property rights for patented technologies owned or controlled by the Company. The intellectual property rights granted may be perpetual in nature, or upon the final milestones being met, or can be granted for a defined, relatively short period of time, with the licensee possessing the right to renew the agreement at the end of each contractual term for an additional minimum upfront payment. The Company recognizes licensing fees when there is persuasive evidence of a licensing arrangement, fees are fixed or determinable, delivery has occurred and collectability is reasonably assured.
	An allowance for doubtful accounts is established based on the Company’s best estimate of the amount of probable credit losses in the Company’s existing license fee receivables, using historical experience. The Company reviews its allowance for doubtful accounts periodically. Past due accounts are reviewed individually for collectability.
	Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. To date, this is yet to occur.
	If product development is successful, the Company will recognize revenue from royalties based on licensees’ sales of its products or products using its technologies. Royalties are recognized as earned in accordance with the contract terms when royalties from licensees can be reasonably estimated and collectability is reasonably assured. If royalties cannot be reasonably estimated or collectability of a royalty amount is not reasonably assured, royalties are recognized as revenue when the cash is received.
	The Company recognizes revenue from milestone payments received under collaboration agreements when earned, provided that the milestone event is substantive, its achievability was not reasonably assured at the inception of the agreement, the Company has no further performance obligations relating to the event and collection is reasonably assured. If these criteria are not met, the Company recognizes milestone payments ratably over the remaining period of the Company’s performance obligations under the collaboration agreement. All such recognized revenues are included in collaborative licensing and development revenue in the Company’s consolidated statements of operations.
Estimates	Estimates
	The preparation of financial statements in accordance with GAAP involves the use of estimates and assumptions that affect the recorded amounts of assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results may differ substantially from these estimates. Significant estimates include the fair value and recoverability of the carrying value of intangible assets (patents and licenses), the fair value of options, the fair value of embedded conversion features, warrants and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, based on historical experience and on various other assumptions that it believes to be reasonable under the circumstances. Actual results may differ from estimates.
Concentration of Credit Risk	Concentration of Credit Risk
	The Company maintains its cash in bank deposit accounts (checking) that at times exceed federally insured limits. Approximately $30.3 million is subject to credit risk at January 31, 2015. However, these cash balances are maintained at creditworthy financial institutions. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk.
Fair Value of Financial Instruments	Fair Value of Financial Instruments
	The carrying amounts of financial instruments, including cash, accounts payable and accrued expenses approximated fair value as of the balance sheet date presented, because of the relatively short maturity dates on these instruments. The carrying amounts of the financing arrangements issued approximate fair value as of the balance sheet date presented, because interest rates on these instruments approximate market interest rates after consideration of stated interest rates, anti-dilution protection and associated warrants.
Net Loss per Share	Net Loss per Share
	Basic net income or loss per common share is computed by dividing net income or loss available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share give effect to dilutive options, warrants, convertible debt and other potential Common Stock outstanding during the period. In the case of a net loss the impact of the potential Common Stock resulting from warrants, outstanding stock options and convertible debt are not included in the computation of diluted loss per share, as the effect would be anti-dilutive. In the case of net income the impact of the potential Common Stock resulting from these instruments that have intrinsic value are included in the diluted earnings per share. The table sets forth the number of potential shares of Common Stock that have been excluded from diluted net loss per share.
		As of January 31,
		2015		2014
	Warrants		4,082,248		4,360,441
	Stock Options		477,968		467,923
	Convertible Debt (using the if-converted method)		3,354		3,354
	Total		4,563,570		4,831,718
Stock Based Compensation	Stock Based Compensation
	The Company has an equity plan which allows for the granting of stock options to its employees, directors and consultants for a fixed number of shares with an exercise price equal to the fair value of the shares at date of grant. The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally measured based on contractual terms. The fair value amount is then recognized over the requisite service period, usually the vesting period, in both research and development expenses and general and administrative expenses on the statement of operations depending on the nature of the services provided by the employees or consultants.
	The process of estimating the fair value of stock-based compensation awards and recognizing stock-based compensation cost over their requisite service period involves significant assumptions and judgments. The Company estimates the fair value of stock option awards on the date of grant using the Black Scholes Model (“BSM”) for the remaining awards, which requires that the Company makes certain assumptions regarding: (i) the expected volatility in the market price of its Common Stock; (ii) dividend yield; (iii) risk-free interest rates; and (iv) the period of time employees are expected to hold the award prior to exercise (referred to as the expected holding period). As a result, if the Company revises its assumptions and estimates, stock-based compensation expense could change materially for future grants.
	The Company accounts for stock-based compensation using fair value recognition and records stock-based compensation as a charge to earnings net of the estimated impact of forfeited awards. As such, the Company recognizes stock-based compensation cost only for those stock-based awards that are estimated to ultimately vest over their requisite service period, based on the vesting provisions of the individual grants.
Recent Accounting Pronouncements	Recent Accounting Pronouncements
	In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers. Amendments in this ASU create Topic 606, Revenue from Contracts with Customers, and supersede the revenue recognition requirements in Topic 605, Revenue Recognition, including most industry-specific revenue recognition guidance throughout the Industry Topics of the Codification. In addition, the amendments supersede the cost guidance in Subtopic 605-35, Revenue Recognition—Construction-Type and Production-Type Contracts, and create new Subtopic 340-40, Other Assets and Deferred Costs—Contracts with Customers. In summary, the core principle of Topic 606 is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This ASU is the final version of Proposed ASU 2011-230—Revenue Recognition (Topic 605) and Proposed ASU 2011–250—Revenue Recognition (Topic 605): Codification Amendments, both of which have been deleted. The amendments in this ASU are effective for the Company for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. The Company is currently evaluating the effects of ASU 2014-09 on the consolidated financial statements.
	In January 2015, the FASB issued ASU 2015-01, Income Statement —Extraordinary and Unusual Items. The objective of this Update is to simplify the income statement presentation requirements in Subtopic 225-20 by eliminating the concept of extraordinary items. Extraordinary items are events and transactions that are distinguished by their unusual nature and by the infrequency of their occurrence. Eliminating the extraordinary classification simplifies income statement presentation by altogether removing the concept of extraordinary items from consideration. This Accounting Standards Update is the final version of Proposed Accounting Standards Update 2014-220—Income Statement—Extraordinary Items (Subtopic 225-20), which has been deleted. The amendments in this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. This Update is not expected to have a material impact on the Company’s financial statements.
	Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on the accompanying condensed financial statements.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies and Basis of Presentation (Tables)	3 Months Ended
	Jan. 31, 2015
Accounting Policies [Abstract]
Schedule of Diluted Net Loss Per Share	The table sets forth the number of potential shares of Common Stock that have been excluded from diluted net loss per share.
		As of January 31,
		2015		2014
	Warrants		4,082,248		4,360,441
	Stock Options		477,968		467,923
	Convertible Debt (using the if-converted method)		3,354		3,354
	Total		4,563,570		4,831,718

Property_and_Equipment_Tables

Property and Equipment (Tables)	3 Months Ended
	Jan. 31, 2015
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment consists of the following:
		January 31, 2015			October 31, 2014
			(Unaudited)
	Laboratory Equipment	$	333,727		$	333,727
	Accumulated Depreciation		(263,260	)		(256,358	)
	Net Property and Equipment	$	70,467		$	77,369

Intangible_Assets_Tables

Intangible Assets (Tables)	3 Months Ended
	Jan. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of Intangible Assets	The following is a summary of intangible assets as of the end of the following fiscal periods:
		January 31, 2015			October 31, 2014
			(Unaudited)
	License	$	651,992		$	651,992
	Patents		3,312,911			3,111,624
	Total intangibles		3,964,903			3,763,616
	Accumulated Amortization		(1,043,974	)		(995,671	)
	Intangible Assets	$	2,920,929		$	2,767,945
Schedule of Amortization Expense	Estimated amortization expense for the next five years is as follows:
	Year ended October 31,
	2015 (Remaining)		148,500
	2016		198,000
	2017		198,000
	2018		198,000
	2019		198,000

Accrued_Expenses_Tables

Accrued Expenses (Tables)	3 Months Ended
	Jan. 31, 2015
Payables and Accruals [Abstract]
Schedule of Accrued Expenses	The following table represents the major components of accrued expenses:
		January 31, 2015		October 31, 2014
		(Unaudited)
	Salaries and Other Compensation	$	583,895	$	890,069
	Vendors		420,002		121,200
	Professional Fees		205,401		208,000
	Withholding Taxes Payable		47,962		22,527
		$	1,257,260	$	1,241,796

Derivative_Instruments_Tables

Derivative Instruments (Tables)	3 Months Ended
	Jan. 31, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Warrants Activity	A summary of changes in warrants for the three months ended January 31, 2015 is as follows:
		Number of			Weighted-Average
		Warrants			Exercise Price
	Outstanding Warrants at October 31, 2014:		4,158,092		$	5.42
	Issued		2,361		$	7.2
	Exercised		-			-
	Expired		(78,205	)	$	9.79
	Outstanding Warrants at January 31, 2015		4,082,248		$	5.21
Schedule of Fair Value of Warrant Liability	In fair valuing the warrant liability, at January 31, 2015 and October 31, 2014, the Company used the following inputs in its BSM:
			1/31/15			10/31/14
	Exercise Price:	$	5.63-18.75		$	2.76-21.25
	Stock Price	$	9.85		$	3.18
	Expected term:		31-914 days			4-1006 days
	Volatility %		97.11%-184.64	%		55.41%-129.38	%
	Risk Free Rate:		.01%-.77	%		.01%-1.62	%

Stock_Options_Tables

Stock Options (Tables)	3 Months Ended
	Jan. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of Changes in Stock Option Plan	A summary of changes in the stock option plan for three months ended January 31, 2015 is as follows:
		Number of			Weighted-Average
		Options			Exercise Price
	Outstanding at October 31, 2014:		467,968		$	15.51
	Granted		20,000		$	2.92
	Exercised		(4,229	)	$	4.08
	Expired		(5,771	)	$	4.08
	Outstanding at January 31, 2015		477,968		$	15.22
	Vested and Exercisable at January 31, 2015		446,035		$	15.69

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	3 Months Ended
	Jan. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Schedule of Allocation of Base Salary	The table below reflects the purchases of each Executive:
		ANNUALIZED
		Annual Amount		For the Three Months Ended January 31, 2015
		to be Purchased		Gross Purchase				Net Purchase
	Executive	$		$		# of		$		# of
						shares				shares
	Daniel J. O’Connor	$	85,647	$	22,294		3,777	$	22,294		3,777
	David J. Mauro	$	15,918	$	4,256		726	$	3,290		580
	Gregory T. Mayes	$	20,951	$	5,453		924	$	4,425		773
	Robert G. Petit	$	25,145	$	6,610		1,123	$	4,856		882
	Sara M. Bonstein	$	17.651	$	4,617		783	$	3,632		630

Fair_Value_Tables

Fair Value (Tables)	3 Months Ended
	Jan. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value, Liabilities Measured on Recurring Basis	The following table provides the liabilities carried at fair value measured on a recurring basis as of January 31, 2015 and October 31, 2014:
	January 31, 2015		Level 1		Level 2		Level 3		Total
	Common stock warrant liability, warrants exercisable at $2.76 - $21.25 from February 2015 through August 2017	$	-	$		$	304,331	$	304,331
	October 31, 2014		Level 1		Level 2		Level 3		Total
	Common stock warrant liability, warrants exercisable at $2.76 - $21.25 from November 2014 through August 2017	$	-	$		$	32,091	$	32,091
Instruments Classified In Shareholders' Equity Measured on Recurring Basis, Unobservable Input Reconciliation	Common stock warrant liability:
		January 31, 2015
		(Unaudited)
	Beginning balance: October 31, 2014	$	32,091
	Issuance of additional warrants due to anti-dilution provisions		8,169
	Change in fair value		264,071
	Balance at January 31, 2015	$	304,331

Organization_Details_Narrative

Organization (Details Narrative) (USD $)	0 Months Ended	3 Months Ended
	Dec. 19, 2014	Jan. 31, 2015
		Patient
Number of patients		110
Number of shares issued during period for registered direct offering	3,940,801
18-Feb-15
Number of shares issued during period for registered direct offering		3,068,095
Proceeds from registered direct offering		15,800,000
19-Feb-15
Proceeds from registered direct offering		22,300,000

Summary_of_Significant_Account3

Summary of Significant Accounting Policies and Basis of Presentation (Details Narrative) (USD $)	3 Months Ended
	Jan. 31, 2015
Accounting Policies [Abstract]
Concentration risk credit risk financial instrument maximum exposure	$30,300,000

Summary_of_Significant_Account4

Summary of Significant Accounting Policies and Basis of Presentation - Schedule of Diluted Net Loss Per Share (Details)	3 Months Ended
	Jan. 31, 2015	Jan. 31, 2014
Number of potential shares of Common Stock that have been excluded from diluted net loss per share	4,563,570	4,831,718
Warrant [Member]
Number of potential shares of Common Stock that have been excluded from diluted net loss per share	4,082,248	4,360,441
Stock Options [Member]
Number of potential shares of Common Stock that have been excluded from diluted net loss per share	477,968	467,923
Convertible Debt [Member]
Number of potential shares of Common Stock that have been excluded from diluted net loss per share	3,354	3,354

Property_and_Equipment_Details

Property and Equipment (Details Narrative) (USD $)	3 Months Ended
	Jan. 31, 2015	Jan. 31, 2014
Property, Plant and Equipment [Abstract]
Depreciation expense	$6,902	$6,903

Property_and_Equipment_Schedul

Property and Equipment - Schedule of Property and Equipment (Details) (USD $)	Jan. 31, 2015	Oct. 31, 2014
Property, Plant and Equipment [Abstract]
Laboratory Equipment	$333,727	$333,727
Accumulated Depreciation	-263,260	-256,358
Net Property and Equipment	$70,467	$77,369

Intangible_Assets_Details_Narr

Intangible Assets (Details Narrative) (USD $)	3 Months Ended
	Jan. 31, 2015	Jan. 31, 2014
Amortization expense of licensed technology and capitalized patent costs	$48,303	$41,934
Minimum [Member]
Finite lived patents expirations	2015
Maximum [Member]
Finite lived patents expirations	2028

Intangible_Assets_Summary_of_I

Intangible Assets - Summary of Intangible Assets (Details) (USD $)	Jan. 31, 2015	Oct. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
License	$651,992	$651,992
Patents	3,312,911	3,111,624
Total intangibles	3,964,903	3,763,616
Accumulated Amortization	-1,043,974	-995,671
Intangible Assets	$2,920,929	$2,767,945

Intangible_Assets_Schedule_of_

Intangible Assets - Schedule of Amortization Expense (Details) (USD $)	Jan. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
2015 (Remaining)	$148,500
2016	198,000
2017	198,000
2018	198,000
2019	$198,000

Accrued_Expenses_Schedule_of_A

Accrued Expenses - Schedule of Accrued Expenses (Details) (USD $)	Jan. 31, 2015	Oct. 31, 2014
Payables and Accruals [Abstract]
Salaries and Other Compensation	$583,895	$890,069
Vendors	420,002	121,200
Professional Fees	205,401	208,000
Withholding Taxes Payable	47,962	22,527
Accrued Liabilities, Current	$1,257,260	$1,241,796

ShortTerm_Convertible_Notes_Fa1

Short-Term Convertible Notes & Fair Value of Embedded Derivative (Details Narrative) (USD $)	Jan. 31, 2015	Oct. 31, 2014
Debt Disclosure [Abstract]
Short-term Convertible Notes and Fair Value of Embedded Derivative	$62,882	$62,882

Derivative_Instruments_Details

Derivative Instruments (Details Narrative) (USD $)	3 Months Ended		12 Months Ended
	Jan. 31, 2015	Jan. 31, 2014	Oct. 31, 2014	Oct. 01, 2014
Warrants outstanding	4,082,248		4,158,092
Exercise price per share	$5.21		$5.42
Fair value of warrant liability	$32,000
Fair value of embedded derivative	304,000		32,000
Gain (loss) on change in fair value of common stock warrant liability and embedded derivative liability	($264,071)	$131,948
Anti-dilution provision	30,000
Anti-dilution provision warrant	30,400
Anti-dilution warrants expired	47,805
Anti-dilution provisions warrants exercise price	$25
Anti-dilution provision warrants period	5 years
Warrants exercise price	$7.20		$7.71
Anti-dilution provisions additional warrants issuable	2,400
Minimum [Member]
Exercise price per share	$2.76		$2.76
Maximum [Member]
Exercise price per share	$21.25		$21.25
Warrant [Member] | Minimum [Member]
Exercise price per share	$2.76
Warrant [Member] | Maximum [Member]
Exercise price per share	$21.25
Warrant [Member]
Warrants outstanding	4,100,000
Common Stock [Member]
Warrants outstanding	4,082,248
Equity Warrants [Member]
Warrants outstanding	4,000,000		4,100,000
Warrant [Member]
Warrants outstanding			4,200,000
Liability Warrant [Member]
Warrants outstanding	4,100,000		4,200,000
Embedded derivative liability outstanding	61,000		123,000
Liability Warrants One [Member]
Weighted average anti-dilutive warrants	32,000		60,000
Liability Warrants Two [Member]
Weighted average anti-dilutive warrants	61,000			123,000
Warrants With Anti Dilution Provisions [Member] | Minimum [Member]
Anti-dilution provisions warrants exercise price			$6
Probability of exercise of additional warrants at exercise price one			40.00%
Probability of exercise of additional warrants at exercise price two			50.00%
Warrants With Anti Dilution Provisions [Member] | Maximum [Member]
Anti-dilution provisions warrants exercise price			$7.20
Probability of exercise of additional warrants at exercise price one			50.00%
Probability of exercise of additional warrants at exercise price two			60.00%

Derivative_Instruments_Schedul

Derivative Instruments - Schedule of Warrants Activity (Details) (USD $)	3 Months Ended
	Jan. 31, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Number of Warrants, Outstanding, Beginning balance	4,158,092
Number of Warrants, Issued	2,361
Number of Warrants, Exercised
Number of Warrants, Expired	-78,205
Number of Warrants, Outstanding, Ending balance	4,082,248
Weighted-Average Exercise Price, Outstanding, Beginning	$5.42
Weighted-Average Exercise Price, Issued	$7.20
Weighted-Average Exercise Price, Exercised
Weighted-Average Exercise Price, Expired	$9.79
Weighted-Average Exercise Price, Outstanding, Ending	$5.21

Derivative_Instruments_Schedul1

Derivative Instruments - Schedule of Fair Value of Warrant Liability (Details) (USD $)	3 Months Ended	12 Months Ended
	Jan. 31, 2015	Oct. 31, 2014
Stock Price	$9.85	$3.18
Minimum [Member]
Exercise Price:	$5.63	$2.76
Expected term:	31 days	4 days
Volatility %	97.11%	55.41%
Risk Free Rate:	0.01%	0.01%
Maximum [Member]
Exercise Price:	$18.75	$21.25
Expected term:	914 days	1006 days
Volatility %	184.64%	129.38%
Risk Free Rate:	0.77%	1.62%

Stock_Options_Details_Narrativ

Stock Options (Details Narrative) (USD $)	3 Months Ended
	Jan. 31, 2015	Jan. 31, 2014
Total compensation cost	$146,846	$257,486
Number of Options, Granted	20,000	0
Fair value of option granted	57,600
Unrecognized compensation cost related to non-vested stock option awards	125,000
Non-vested stock option awards remaining average vesting period	6 months
Aggregate intrinsic value of outstanding options	282,000
Research and Development Expenses [Member]
Total compensation cost	45,229	90,380
General and Administrative Expenses [Member]
Total compensation cost	$101,627	$167,106

Stock_Options_Summary_of_Chang

Stock Options - Summary of Changes in Stock Option Plan (Details) (USD $)	3 Months Ended
	Jan. 31, 2015	Jan. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Number of Options, Outstanding, Beginning balance	467,968
Number of Options, Granted	20,000	0
Number of Options, Exercised	-4,229
Number of Options, Cancelled or Expired	-5,771
Number of Options, Outstanding, Ending Balance	477,968
Number of Options, Vested and Exercisable	446,035
Weighted-Average Exercise Price, Outstanding, Beginning	$15.51
Weighted-Average Exercise Price, Granted	$2.92
Weighted-Average Exercise Price, Exercised	$4.08
Weighted-Average Exercise Price, Cancelled or Expired	$4.08
Weighted-Average Exercise Price, Outstanding, Ending	$15.22
Weighted-Average Exercise Price, Vested and Exercisable	$15.69

Commitments_and_Contingencies_1

Commitments and Contingencies (Details Narrative) (USD $)	1 Months Ended	3 Months Ended	0 Months Ended	1 Months Ended
	Dec. 31, 2014	Jan. 31, 2015	Jun. 19, 2009	Mar. 31, 2014	Oct. 31, 2013	Apr. 02, 2011	Mar. 24, 2014
						sqft
Stock compensation expense		$46,153
Share-based compensation, common stock, shares		7,832
Share-based compensation, shares on net basis after employee payroll taxes		7,053
Issuance of common stock		190,000
Cash received from sale of NOL's	1,731,317
Area of lease						10,000
Director [Member]
Stock compensation expense		606,539
Share-based compensation, common stock, shares		191,939
Share-based compensation, shares on net basis after employee payroll taxes		178,513
Numoda Corporation [Member]
Amount owed by numoda			540,000
2013 Base Salary Stock [Member]
Issuance of common stock		34,752
Number of stock shares issued during period amount		182,919
2014 Cash Bonus Equity [Member]
Issuance of common stock		206,125
Number of stock shares issued during period amount		57,990
2014 Voluntary Request To Purchase Of Equity [Member]
Issuance of common stock		15,950
Number of stock shares issued during period amount		68,750
Common Stock [Member]
Issuance of common stock				3,333	13,500
Number of stock shares issued during period amount				10,000	54,000
Promissory Note One [Member]
Issuance of common stock		21,091
Number of stock shares issued during period amount		66,500
Daniel J. O' Connor [Member]
Issuance of common stock		146,616
Number of stock shares issued during period amount		588,294
Sara M. Bonstein [Member] | Stock Bonus Award [Member]
Percentage of bonus paid		75.00%
Total fair value of bonus shares issued		457,125
Bonus shares issued		137,275
Bonus shares issued on net basis after employee payroll taxes		104,461
Dr. Petit [Member] | Stock Bonus Award [Member]
Percentage of bonus paid		100.00%
Executive Officers [Member] | Stock Bonus Award [Member]
Total fair value of bonus shares issued		133,699
Bonus shares issued		34,094
Bonus shares issued on net basis after employee payroll taxes		27,566
Non Executive Employees [Member] | Stock Bonus Award [Member]
Total fair value of bonus shares issued		28,164
Bonus shares issued		8,458
Bonus shares issued on net basis after employee payroll taxes		8,442
Iliad Research and Trading, L.P. [Member]
Damages on claim plus interest, attorneys' fees and costs							$300,000

Commitments_and_Contingencies_2

Commitments and Contingencies - Schedule of Allocation of Base Salary (Details) (USD $)	3 Months Ended
	Jan. 31, 2015	Jan. 31, 2014
Annual Amount to be Purchased	$2,030,170	$1,602,423
Cumulative Net Purchase	15,772,331	400,000
Daniel J. O' Connor [Member]
Annual Amount to be Purchased	85,647
Cumulative Gross Purchase	22,294
Cumulative shares Gross Purchase	3,777
Cumulative Net Purchase	22,294
Cumulative shares Net Purchase	3,777
David J. Mauro [Member]
Annual Amount to be Purchased	15,918
Cumulative Gross Purchase	4,256
Cumulative shares Gross Purchase	726
Cumulative Net Purchase	3,290
Cumulative shares Net Purchase	580
Gregory T. Mayes [Member]
Annual Amount to be Purchased	20,951
Cumulative Gross Purchase	5,453
Cumulative shares Gross Purchase	924
Cumulative Net Purchase	4,425
Cumulative shares Net Purchase	773
Robert G. Petit [Member]
Annual Amount to be Purchased	25,145
Cumulative Gross Purchase	6,610
Cumulative shares Gross Purchase	1,123
Cumulative Net Purchase	4,856
Cumulative shares Net Purchase	882
Sara M. Bonstein [Member]
Annual Amount to be Purchased	17,651
Cumulative Gross Purchase	4,617
Cumulative shares Gross Purchase	783
Cumulative Net Purchase	$3,632
Cumulative shares Net Purchase	630

Shareholders_Equity_Details_Na

Shareholders' Equity (Details Narrative) (USD $)	0 Months Ended	3 Months Ended
	Dec. 19, 2014	Jan. 31, 2015
Number of shares issued during period for registered direct offering	3,940,801
Registered Direct Offering [Member]
Common stock price per share	4.25
Proceeds from received from offering	16,700,000
Proceeds from registered direct offering, net of offering expenses	15,800,000
Consultants [Member] | Investors Relation Services [Member]
Stock issued during period for services		90,000
Stock issued during period value for services		698,100
Consultants [Member] | Research And Development Services [Member]
Stock issued during period for services		30,000
Stock issued during period value for services		$93,900

Fair_Value_Fair_Value_Liabilit

Fair Value - Fair Value, Liabilities Measured on Recurring Basis (Details) (USD $)	Jan. 31, 2015	Oct. 31, 2014
Common stock warrant liability, warrants exercisable	$304,331	$32,091
Fair Value, Inputs, Level 1 [Member]
Common stock warrant liability, warrants exercisable
Fair Value, Inputs, Level 2 [Member]
Common stock warrant liability, warrants exercisable
Fair Value, Inputs, Level 3 [Member]
Common stock warrant liability, warrants exercisable	$304,331	$32,091

Fair_Value_Fair_Value_Liabilit1

Fair Value - Fair Value, Liabilities Measured on Recurring Basis (Details) (Parenthetical) (USD $)	3 Months Ended	12 Months Ended
	Jan. 31, 2015	Oct. 31, 2014
Exercise Price	$5.21	$5.42
Warrants exercisable period	February 2015 through August 2017	November 2014 through August 2017
Minimum [Member]
Exercise Price	$2.76	$2.76
Maximum [Member]
Exercise Price	$21.25	$21.25

Fair_Value_Instruments_Classif

Fair Value - Instruments Classified In Shareholders' Equity Measured on Recurring Basis, Unobservable Input Reconciliation (Details) (Common Stock Warrant Liability [Member], USD $)	3 Months Ended
	Jan. 31, 2015
Common Stock Warrant Liability [Member]
Beginning balance	$32,091
Issuance of additional warrants due to anti-dilution provisions	8,169
Change in fair value	264,071
Ending Balance	$304,331

Subsequent_Events_Details_Narr

Subsequent Events (Details Narrative) (USD $)	3 Months Ended	0 Months Ended
	Jan. 31, 2015	Feb. 18, 2015	Feb. 19, 2015	Feb. 27, 2015	Mar. 02, 2015	Feb. 26, 2015	Feb. 09, 2015	Feb. 13, 2015
Number of shares issued as per employment agreements	190,000
Subsequent Event [Member]
Number of shares priced registered direct offering common stock		3,068,095
Common stock price per share		$7.50
Gross proceeds from registered direct offering			$23,000,000
Proceeds from registered direct offering, net of offering expenses			22,300,000
Subsequent Event [Member] | Executive Officers [Member]
Shares issued during period				1,434
Subsequent Event [Member] | Accredited Investor [Member]
Common stock issued for services					23,606		37,916
Stock issued during period for converting notes payable						4,104
Value of shares converted into notes payable						$33,333
Subsequent Event [Member] | Executive Officers [Member]
Number of shares issued as per employment agreements								13,233